Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 30Small Cell Lung Carcinoma 13Recurrence 3Melanoma 3Lung Neoplasms 3Advanced Lung Cancer 3NSCLC 2Lymphoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Thoracic Neoplasms 1Stage IB-IIIB NSCLC 1Small Cell Lung Cancer Limited Stage 1Sarcoma 1SCLC, Extensive Stage 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Ovarian Neoplasms 1Non-small Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Non Small Cell Lung Cancer Recurrent 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Lung Diseases 1Local Advanced Non-small Cell Lung Cancer 1Liver Neoplasms 1Kidney Neoplasms 1

Interventions

toripalimab 1anlotinib 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non Small Cell Lung Cancer Recurrent × toripalimab × Thoracic × Clear all
NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Non Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡